Valuation: Cell Source, Inc.

Market Cap 2.44Cr 2.14Cr 1.99Cr 1.83Cr 3.44Cr 235.08Cr 3.49Cr 24Cr 9.25Cr 115.57Cr 9.16Cr 8.97Cr 399.59Cr P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 3.49Cr 3.07Cr 2.85Cr 2.62Cr 4.92Cr 336.27Cr 4.99Cr 34Cr 13Cr 165.32Cr 13Cr 13Cr 571.6Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day+0.78%
1 week-24.42%
Current month-16.43%
1 month-20.73%
3 months-22.62%
6 months-24.51%
Current year+30.00%
1 week 0.53
Extreme 0.531
0.8
1 month 0.53
Extreme 0.531
0.96
Current year 0.41
Extreme 0.4134
2.25
1 year 0.3
Extreme 0.3022
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 30/06/2014
Director TitleAgeSince
Chairman 77 18/05/2015
Director/Board Member 82 25/03/2021
Director/Board Member 72 10/03/2022
Date Insider Type Main position Quantity % Market Cap.
09/08/21 Others

Director

8,00,000 2.4492%
30/06/21 Others

Director

19,440 0.0595%
30/06/21 Others

Director

4,860 0.0149%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-24.42%+62.50%+30,852.38% 4.42Cr
+0.20%+7.06%+57.64%+71.99% 5.73TCr
-1.92%+6.03%+40.64%+80.66% 5.5TCr
-0.06%-1.29%+2.86%+425.15% 2.32TCr
+1.59%-2.35%-22.53%-15.34% 2.26TCr
-1.13%+1.05%+20.81%-7.73% 2.05TCr
+0.63%+1.84%+25.61%-30.07% 1.76TCr
-0.10%+1.88%+34.42%+545.91% 1.57TCr
-1.30%-5.02%+170.77%+310.94% 1.45TCr
+1.52%-0.98%+21.43%+179.36% 1.39TCr
Average +0.05%-1.29%+41.41%+3,241.33% 2.4TCr
Weighted average by Cap. -0.25%+2.09%+38.64%+142.78%

Financials

2023 2024
Net sales - -
Net income -53.21L -46.74L -43.46L -39.88L -74.94L -51Cr -76.09L -5.16Cr -2.02Cr -25Cr -2Cr -1.95Cr -87Cr -45.13L -39.63L -36.86L -33.82L -63.55L -43Cr -64.53L -4.38Cr -1.71Cr -21Cr -1.69Cr -1.66Cr -74Cr
Net Debt 92.74L 81.45L 75.75L 69.51L 1.31Cr 89Cr 1.33Cr 9Cr 3.51Cr 44Cr 3.48Cr 3.41Cr 151.81Cr 1.05Cr 92.29L 85.83L 78.76L 1.48Cr 101.19Cr 1.5Cr 10Cr 3.98Cr 50Cr 3.94Cr 3.86Cr 172.01Cr
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
1
Date Price Change Volume
24/26/24 $0.6500 +0.78% 400
23/26/23 $0.6450 -19.38% 6,500
21/26/21 $0.8000 +25.00% 504
  1. Stock Market
  2. Stocks
  3. CLCS Stock